Have you successfully transfected iCell Cardiomyocytes2? What protocols are available and what reagents have you tested?

Yes, we have successfully transfected iCell® Cardiomyocytes2 with results similar to what we achieved with the iCell Cardiomyocytes, routinely observing the highest efficiency, lowest toxicity, and quickest response using ViaFect Transfection Reagent (Promega). The biggest difference you will note between the two versions of these cells is the shorter workflow enabled by the faster recovery time of the iCell Cardiomyocytes2, which will be ready to transfect at 4 days post-thaw.

Our Application Note highlights RNAi and plasmid DNA transfection techniques for target gene/pathway modulation and reporting in iCell Cardiomyocytes and iCell Cardiomyocytes2 and identifies three advantages of human iPS cell-based systems over traditional primary cell models:

  1. High efficiency/low toxicity transfection
  2. Flexible and prolonged expression windows
  3. Real-time, multiplexed functional readouts

For more details about the delivery of plasmid DNA into iCell Cardiomyocytes using the ViaFect Transfection Reagent, see our Application Protocol. We evaluated several transfection reagents delivery of plasmid DNA, small interfering RNA (siRNA) oligonucleotides, and reporter gene constructs.

For more information about transfection in iCell Cardiomyocytes, see solutions 00000107A, 00000107B, 00000107C, 00000107D 00000107E, 00000107F, and  00000107G

References:

  1. Application Note: Applying Transfection Technologies to Create Novel Screening Models
  2. Application Protocol: Using Liposome-mediated Transfection for Gene Delivery
  3. Webinar Presentation: Efficiently Build Relevant In Vitro Models Using Human Stem Cell-derived Tissue Cells, High Performance Transfection and Novel Multiplexed Reporter Techniques Webinar